“AstraZeneca is proud to partner with CATALIS to expand and accelerate clinical research in Quebec. By using the CATALIS FAST TRACK Evaluation Service, we were able to launch the ARTEMIDE-Lung03 study in non-small cell lung cancer (NSCLC) in just 10.8 weeks. In collaboration with the McGill University Health Centre, we also successfully randomized the first global patient for this expansive phase III study. This is a great collaboration among AstraZeneca, CATALIS, researchers, and healthcare organizations and emphasizes our commitment to advancing rapid access to innovative treatments and improving patient outcomes.”
